GT Biopharma Inc. Common Stock (GTBP)
GT Biopharma Inc. (GTBP) is a biotechnology company focused on developing and commercializing targeted immunotherapies for cancer and other diseases. The company employs its proprietary technologies, including its Tri-specific Killer Engager (TriKE) platform, to design novel agents that harness the immune system to specifically attack cancer cells. GT Biopharma aims to advance innovative treatments through clinical development and strategic collaborations.
Company News
GT Biopharma, a clinical-stage immuno-oncology company, announced it has entered into agreements for the exercise of existing warrants and the issuance of new warrants, raising approximately $0.7 million in gross proceeds.
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. Cutera posted adjusted loss of $1.36 per share, compared to market estimates for a loss of 94 cents per share. The company’s quarterly sales came in at $49.540 million, versus expectat...
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Announced Positive Interim Data Results Demonstrating Substantial Reduction in AML/MDS Cancer Cells… The post GT Biopharma Provides Second Quarter 2021 Business Update appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.